Shares of Cephalon sank more than 4% in Wednesday trading due to worries that the company’s experimental Sparlon drug might be branded with a warning about a possible increased risk of suicide should it be approved.
Shares of Cephalon sank more than 4% in Wednesday trading due to worries that the company’s experimental Sparlon drug might be branded with a warning about a possible increased risk of suicide should it be approved.
